CRA's RADAR Insights: Factors impacting GKV rebates for orphan drugs in Germany - Part 1
Germany’s AMNOG introduced in 2011 follows health technology assessments (HTAs) with reimbursement price negotiations and some exceptions for orphan drugs...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Our team leverages its deep industry knowledge and familiarity with health-care data analytics to help our clients navigate government and regulatory investigations involving civil, criminal, and regulatory enforcement issues. We have expertise in pharmaceutical pricing and reimbursement and the intersection of these areas with government regulations. CRA has experience working with complex data, including Medicare, Medicaid, and private insurance claims data, pharmaceutical sales data, and market research to investigate questions of wrongful conduct, causation and damages. Our experts also serve as monitors during post-merger activities.
Group Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.comGermany’s AMNOG introduced in 2011 follows health technology assessments (HTAs) with reimbursement price negotiations and some exceptions for orphan drugs...
A variety of contraceptive options exist, each with their own pros and cons. Long-acting reversible contraceptives (LARCs), like IUDs, contraceptive...